

RECEIVED

APR 11 2003

TECH CENTER 1600/2900

Docket No.: PF220P1  
(PATENT)



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Ying-Fei Wei

Application No.: 09/726,348

Group Art Unit: 1647

Filed: December 1, 2000

Examiner: L. Spector

For: Transforming Growth Factor Alpha HIII

#21  
S.G.  
4/30/03

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AY-BC listed on the attached Form PTO/SB/08. A copy of each of references AY-BC is enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.


Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Supplemental Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in this application and if accompanied by a Statement as specified in § 1.97(e) or the fee as specified in § 1.17(p).

Accordingly, the undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Supplemental Information Disclosure Statement. In particular, the listed references were cited in a European Search Report (reference BC) mailed March 12, 2003, in connection with a corresponding international application.

Applicants believe that no fee is due in connection with this submission. However, should the Patent & Trademark Office determine otherwise, please charge such fee to our Deposit Account No. 08-3425.

Dated: April 10, 2003

Respectfully submitted,

By   
Lin J. Hymel  
Registration No.: 45,414  
HUMAN GENOME SCIENCES, INC.  
9410 Key West Avenue  
Rockville, MD 20850  
Attorney for Applicants  
(301) 251-2723

PTO  
APR 10 2003

TRADEMARK OFFICE

PTO/SB/17 (01-03)

Approved for use through 04/30/2003. OMB 0651-0032  
Information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 0.00

## Complete if Known

Application Number 09/726,348-Conf. #3638  
Filing Date December 1, 2000  
First Named Inventor Ying-Fei Wei  
Examiner Name L. Spector  
Group Art Unit 1647  
Attorney Docket No. PF220P1

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account

Deposit Account Number

08-3425

Deposit Account Name

Human Genome Sciences, Inc.

The Commissioner is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee

to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	2001	750	375	2001	375	Utility filing fee	
1002	2002	330	165	2002	165	Design filing fee	
1003	2003	520	260	2003	260	Plant filing fee	
1004	2004	750	375	2004	375	Reissue filing fee	
1005	2005	160	80	2005	80	Provisional filing fee	
SUBTOTAL (1)							(\$)
							0.00

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims			
Multiple Dependent			

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1202	2202	18	9	2202	9	Claims in excess of 20	
1201	2201	84	42	2201	42	Independent claims in excess of 3	
1203	2203	280	140	2203	140	Multiple dependent claim, if not paid	
1204	2204	84	42	2204	42	** Reissue independent claims over original patent	
1205	2205	18	9	2205	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)							(\$)
							0.00

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	2051	130	65	2051	65	Surcharge - late filing fee or oath	
1052	2052	50	25	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	1053	130	130	1053	130	Non-English specification	
1812	1812	2,520	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	1804	920*	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1805	1,840*	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	2251	110	55	2251	55	Extension for reply within first month	
1252	2252	410	205	2252	205	Extension for reply within second month	
1253	2253	930	465	2253	465	Extension for reply within third month	
1254	2254	1,450	725	2254	725	Extension for reply within fourth month	
1255	2255	1,970	985	2255	985	Extension for reply within fifth month	
1401	2401	320	160	2401	160	Notice of Appeal	
1402	2402	320	160	2402	160	Filing a brief in support of an appeal	
1403	2403	280	140	2403	140	Request for oral hearing	
1451	2451	1,510	755	2451	755	Petition to institute a public use proceeding	
1452	2452	110	55	2452	55	Petition to revive - unavoidable	
1453	2453	1,300	650	2453	650	Petition to revive - unintentional	
1501	2501	1,300	650	2501	650	Utility issue fee (or reissue)	
1502	2502	470	235	2502	235	Design issue fee	
1503	2503	630	315	2503	315	Plant issue fee	
1460	1460	130	130	1460	130	Petitions to the Commissioner	
1807	1807	50	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	1806	180	180	1806	180	Submission of Information Disclosure Stmt	
8021	8021	40	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	2809	750	375	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	2810	750	375	2810	375	For each additional invention to be examined (37CFR 1.129(b))	
1801	2801	750	375	2801	375	Request for Continued Examination (RCE)	
1802	1802	900	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

## SUBMITTED BY

Name (Print/Type) Lin J. Hymel

Registration No. (Attorney/Agent)

45,414

## Complete (if applicable)

Telephone (301) 251-6015

Signature

*Lin J. Hymel*

Date

April 10, 2003

RECEIVED  
APR 11 2003  
TECH CENTER 1600/2900

O I P E  
APR 10 2003  
U.S. PATENT & TRADEMARK OFFICE

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/726,348
				Filing Date	December 1, 2000
				First Named Inventor	Ying-Fei Wei
				Art Unit	1647
				Examiner Name	L. Spector
Sheet	1	of	1	Attorney Docket Number	PF220P1

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
<i>AS</i>	AY	PCT-99/18203-A2	04-15-1999	Sagami Chemical Research Center and Protegene Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>AS</i>	AZ	KUMAR et al., "Transforming growth factor alpha", <i>Biopolymers</i> , 19(5):373-387 (1995)	
<i>AS</i>	BA	NORMANNO et al. "Epidermal growth factor--related peptides as targets for experimental therapy of human colon carcinoma", <i>Cancer Detection and Prevention</i> 22(1):62-67 (1998)	
<i>AS</i>	BB	MCINNES et al., "Growth factor receptors: structure, mechanism, and drug discovery", <i>Cell Biol. Int'l.</i> 43(5):339-366 (1997)	
<i>AS</i>	BC	Partial European Search Report, Application No. EP 00 98 3862, dated March 12, 2003	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>L. Spector</i>	Date Considered	6/23/03
--------------------	-------------------	-----------------	---------